A Phase I Study of Talimogene Laherparepvec and Panitumumab in Patients with Locally Advanced Squamous Cell Carcinoma of the Skin (SCCS)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Squamous Cell Carcinoma
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Histologically confirmed squamous cell carcinoma of the skin (SCCS) that is a) locally advanced or metastatic for which curative surgery or radiation would be difficult or impossible or b) recurrent after initial surgery, chemotherapy, or radiation therapy, or c) considered to have aggressive features including the following: tumors 2 cm or more, tumors invading deep tissues such as muscle, cartilage or bone; tumors showing perineural invasion, and/or tumors metastatic to loco-regional lymph nodes. 2) Eastern Cooperative Oncology Group (ECOG) performance status =< 2. 3) No prior treatment with panitumumab or talimogene laherparepvec for advanced disease.

You may not be eligible for this study if the following are true:

  • 1) Pregnant women. 2) History of allergic reactions attributed to compounds of similar chemical or biologic composition to panitumumab, talimogene laherparepvec or other agents used in the study and history of interstitial pneumonitis, pulmonary fibrosis, or evidence of interstitial pneumonitis.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.